Header
For Healthcare Professionals

Global guidelines recommend SGLT2i to reduce CV risk for patients with T2D, HF, and/or CKD1-10

The interconnectivity of cardio, renal, and metabolic diseases amplifies and accelerates risk11, as evidenced by the latest treatment guidelines that emphasize the importance of reducing the risk of CV events and/or disease progression in patients with T2D, HF, and/or CKD.1-10

Global guidelines recommend SGLT2i to reduce CV risk for patients with T2D, HF, andor CKD1-10
Global guidelines recommend SGLT2i to reduce CV risk for patients with T2D, HF, andor CKD1-10

Jardiance Met® combines the CV death risk reduction of JARDIANCE in a single pill with metformin*14

Jardiance Met® combines the CV death risk reduction of JARDIANCE in a single pill with metformin14
Jardiance Met® combines the CV death risk reduction of JARDIANCE in a single pill with metformin14

  1. Standards of care in diabetes—2023. Khan SE, ed. Diabetes Care. 2023;46(suppl 1):S1-S291.

  2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786.

  3. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090.

  4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [published correction appears in Eur Heart J. 2020 Dec 1;41(45):4317]. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486

  5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368

  6. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published online ahead of print, 2023 Aug 25]. Eur Heart J. 2023;ehad195. doi:10.1093/eurheartj/ehad195

  7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association.

  8. McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):531-546. doi:10.1016/j.cjca.2021.01.017

  9. Rossing P, Caramori ML, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int. 2022;102(5):990-999.

  10. Levin A, Stevens P, et al. KDIGO 2023 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Public Review Draft. July 2023. Accessed January 17, 2024. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf

  11. Kalra S, Aydin H, Sahay M, et al. Cardiorenal syndrome in type 2 diabetes mellitus—rational use of sodium-glucose cotransporter-2 inhibitors. Eur Endocrinol. 2020;16(2):113-121.

  12. Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(45).

  13. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2025. Diabetes Care. 2024;48(suppl 1):S181–S206.

  14. Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME® Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

  15. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-1659.

  16. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle H, Broedl U; EMPA-REG H2H-SU Trial Investigators. Comparison of empagliflozin and glimepiride as addon to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691-700.

  17. Inzucchi SE, Davies MJ, Khunti K, et al. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):425-433.

  18. Jardiance Met® India prescribing information dated April 2025.

  • *
    In a subgroup analysis at 24 weeks, of patients with baseline 28.5%, adjusted mean changes in HbA1c were -0.5% for placebo (n=50), -1.2% for Empagliflozin 10 mg (n=57), and -1.5% for Empagliflozin 25 mg (n=48). Difference from placebo (adjusted mean) was -0.739 for Empagliflozin 10 mg and -1.0% for Empagliflozin 25 mg.17
  • †
    Adjusted mean changes of -0.45 kg reduction in body weight from baseline 79.7 kg for placebo (n-207), -2.08 kg from baseline 81.6 kg for Empagliflozin 10 mg (n-217), and -2.46 kg from baseline 82.2 kg for Empagliflozin 25 mg; P<0.001 versus placebo for both doses.18